Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Intradermal Diluent (HSA with Phenol) is a sterile pharmaceutical solution composed of saline, human serum albumin (HSA), and phenol, primarily used as a negative control in clinical allergy research. In the context of the National Institute of Allergy and Infectious Diseases (NIAID) Phase 0 trial (NCT01292070) for cat allergy, this diluent was administered intradermally to healthy volunteers. Its role is to provide a baseline for skin reactivity, such as wheal and flare responses, ensuring that any observed reactions to experimental agents like the GFD fusion protein or cat hair extracts are accurately attributed to the active substances rather than the injection procedure or the vehicle components.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Intradermal Diluent (HSA with Phenol).